Trastuzumab-deruxtecan: an investigational agent for the treatment of HER2-positive breast cancer

Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study

(2020) Shanu Modi et al.   JOURNAL OF CLINICAL ONCOLOGY

TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases

(2019) Rachel A. Freedman et al.   JOURNAL OF CLINICAL ONCOLOGY

[fam‐] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification

(2019) Naoki Takegawa et al.   INTERNATIONAL JOURNAL OF CANCER

SOPHIA primary analysis: A phase 3 (P3) study of margetuximab (M) + chemotherapy (C) versus trastuzumab (T) + C in patients (pts) with HER2+ metastatic (met) breast cancer (MBC) after prior anti-HER2 therapies (Tx).

(2019) Hope S. Rugo et al.   JOURNAL OF CLINICAL ONCOLOGY

Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial.

(2019) Cristina Saura et al.   JOURNAL OF CLINICAL ONCOLOGY

Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer

(2019) Collins et al.   Cancers

Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study

(2019) Kohei Shitara et al.   LANCET ONCOLOGY

Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study

(2019) Kenji Tamura et al.   LANCET ONCOLOGY

Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study

(2019) Udai Banerji et al.   LANCET ONCOLOGY

Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer

(2019) Rashmi K. Murthy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer

(2019) Shanu Modi et al.   NEW ENGLAND JOURNAL OF MEDICINE

4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†

(2018) F Cardoso et al.   ANNALS OF ONCOLOGY

Cancer statistics, 2018

(2018) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Single agent activity of ZW25, a HER2-targeted bispecific antibody, in heavily pretreated HER2-expressing cancers.

(2018) Funda Meric-Bernstam et al.   JOURNAL OF CLINICAL ONCOLOGY

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

(2018) Peter Schmid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

(2018) Gunter von Minckwitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance

(2017) Naoki Takegawa et al.   INTERNATIONAL JOURNAL OF CANCER

Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study

(2017) Toshihiko Doi et al.   LANCET ONCOLOGY

Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial

(2017) Ian E Krop et al.   LANCET ONCOLOGY

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

(2017) Mark Robson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer

(2017) Gunter von Minckwitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

New insights into the metastatic behavior after breast cancer surgery, according to well-established clinicopathological variables and molecular subtypes

(2017) Oreste Claudio Buonomo et al.   PLoS One

Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity

(2016) Yusuke Ogitani et al.   CANCER SCIENCE

DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1

(2016) Y. Ogitani et al.   CLINICAL CANCER RESEARCH

Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases

(2016) Rachel A. Freedman et al.   JOURNAL OF CLINICAL ONCOLOGY

Activity of T-DM1 in Her2-positive breast cancer brain metastases

(2015) Rupert Bartsch et al.   CLINICAL & EXPERIMENTAL METASTASIS

Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer

(2015) Sandra M. Swain et al.   NEW ENGLAND JOURNAL OF MEDICINE

Systemic Therapy of Brain Metastases

(2014) Harry C. Brastianos et al.   Current Neurology and Neuroscience Reports

Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial

(2014) Ian E Krop et al.   LANCET ONCOLOGY

Metastatic breast cancer: are we treating the same patients as in the past?

(2013) M.-P. Ufen et al.   ANNALS OF ONCOLOGY

HER2 testing: Current status and future directions

(2013) Edith A. Perez et al.   CANCER TREATMENT REVIEWS

Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study

(2012) Thomas Bachelot et al.   LANCET ONCOLOGY

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

(2012) Sunil Verma et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of Tumor Subtype on Survival and the Graded Prognostic Assessment for Patients With Breast Cancer and Brain Metastases

(2011) Paul W. Sperduto et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

In Vivo Characterization of Changing Blood-Tumor Barrier Permeability in a Mouse Model of Breast Cancer Metastasis

(2011) Dean B. Percy et al.   INVESTIGATIVE RADIOLOGY

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

(2011) Brian D. Lehmann et al.   JOURNAL OF CLINICAL INVESTIGATION

Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer

(2011) José Baselga et al.   NEW ENGLAND JOURNAL OF MEDICINE

Predicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer

(2009) Rupert Bartsch et al.   BMC CANCER

Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer

(2009) N. U. Lin et al.   CLINICAL CANCER RESEARCH

Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial

(2009) Eric L Chang et al.   LANCET ONCOLOGY

Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate

(2008) G. D. Lewis Phillips et al.   CANCER RESEARCH